相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors
Martine J. Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
Bishal Gyawali et al.
ECLINICALMEDICINE (2020)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Everardo D. Saad et al.
LANCET ONCOLOGY (2019)
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Bishal Gyawali et al.
JAMA INTERNAL MEDICINE (2019)
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2019)
Current state of quality of life and patient-reported outcomes research
Andrew Bottomley et al.
EUROPEAN JOURNAL OF CANCER (2019)
Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer
Nicola Jane Lawrence et al.
JNCI CANCER SPECTRUM (2018)
Approvals in 2016: questioning the clinical benefit of anticancer therapies
Christopher M. Booth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With NewCancer Medicines
Sebastian Salas-Vega et al.
JAMA ONCOLOGY (2017)
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
S. Michiels et al.
ANNALS OF ONCOLOGY (2016)
Surrogate end points for overall survival in breast cancer trials: A review
Frederic Fiteni et al.
BREAST (2016)
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?
Courtney Davis
SOCIAL SCIENCE & MEDICINE (2015)
Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review
Julien Peron et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Raising the bar for market authorisation of new drugs
Huseyin Naci et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Reputation and Precedent in the Bevacizumab Decision
Daniel Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
Everardo D. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
